Northern Trust Corp lifted its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 5.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,054,365 shares of the biotechnology company's stock after acquiring an additional 58,676 shares during the quarter. Northern Trust Corp owned approximately 0.74% of Aurinia Pharmaceuticals worth $9,468,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of AUPH. Kingswood Wealth Advisors LLC purchased a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $248,000. Union Bancaire Privee UBP SA purchased a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $108,000. China Universal Asset Management Co. Ltd. increased its holdings in Aurinia Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company's stock valued at $273,000 after buying an additional 2,857 shares during the period. Blue Trust Inc. increased its holdings in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after buying an additional 6,174 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $135,000. 36.83% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Aurinia Pharmaceuticals
In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. This trade represents a 8.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. This trade represents a 9.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 343,898 shares of company stock valued at $2,753,094 over the last ninety days. 4.30% of the stock is owned by company insiders.
Aurinia Pharmaceuticals Stock Down 2.3%
AUPH stock traded down $0.19 during trading on Friday, hitting $8.08. 2,007,945 shares of the company's stock traded hands, compared to its average volume of 1,331,142. The firm has a market capitalization of $1.09 billion, a P/E ratio of -53.86 and a beta of 1.16. The business has a fifty day simple moving average of $8.02 and a two-hundred day simple moving average of $8.27. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 1 year low of $5.11 and a 1 year high of $10.67.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.08. The company had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.
Analyst Ratings Changes
Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.
Check Out Our Latest Stock Report on Aurinia Pharmaceuticals
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Articles
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
